针对性抗血小板治疗在喉支架中的结果:一项回顾性比较研究
Pavol Vigláš1,2, Vojtěch Smolka2, Jan Raupach3,4
1Deptartment of Radiology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
CVIR endovascular
|October 8, 2024
概括
通过使用血小板功能测试来定制抗血小板疗法,用于带支架,大大减少了与程序相关的中风和死亡. 这种个性化的方法似乎比标准的双重抗血小板治疗更安全,因此需要进一步调查.
科学领域:
- 心血管医学 心血管医学
- 干预神经病学 干预神经病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状动脉支架需要双重抗血小板治疗来预防血栓栓塞事件.
- 克洛皮多格雷尔耐药性构成这些并发症的持续风险.
- 常规血小板功能测试 (PFT) 被调查以优化抗血小板治疗.
研究的目的:
- 为了确定常规的PFT和调整的抗血小板治疗是否可以减少心血管栓塞并发症和心血管支架后的死亡.
- 将结果与已建立的临床试验数据进行比较.
主要方法:
- 在8年内对241名接受动脉支架治疗的患者进行了回顾性分析.
- 在手术前进行的血小板功能测试以指导抗血小板治疗.
- 评估和与CREST和ICSS试验相比较的与程序相关的中风或死亡发生率 (0-30天).
主要成果:
- 发生了五种血栓栓塞并发症 (2.01%);4种 (1.61%) 是与程序相关的.
- 两例死亡 (0.82%) 是由于手术相关的中风造成的.
- 与相关队列中的CREST (2.01%对4.81%) 和ICSS (2.86%对7.37%) 相比,与程序相关的中风/死亡的发病率较低.
结论:
- 根据PFT指导的定制抗血小板疗法在頸動脈支架中是安全的.
- 这种方法似乎与程序相关死亡或中风的减少率有关.
- 需要进行更大规模的前性研究来证实其优于标准的双重抗血小板治疗.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
480
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
480
01:27Peripheral Artery Disease III: Interprofessional Care
3
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
3
01:27Coronary Artery Disease V: Surgical Management
3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
01:26Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
01:26Angina IV: Management
3
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
3
01:28Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3